Lilly's 2nd Potential Coronavirus Antibody Candidate in Phase I
Zacks Equity Research - June 9, 2020
Eli Lilly & Company’s LLY partner China-based Junshi Biosciences
has dosed the first healthy volunteer in phase I study on JS016,
their antibody candidate for treating COVID-19.
Lilly signed the deal with Junshi last month to co-develop therapeutic
antibodies for the potential prevention and treatment of COVID-19.
Junshi has dosed the patient in a phase I study in China, while Lilly
will soon begin its phase I study in United States.
The phase I studies will evaluate the safety, tolerability, pharmacok-
inetics and immunogenicity of JS016 in healthy participants who have
not been diagnosed with coronavirus.
While Junshi Biosciences has rights to products under the deal in
Greater China, Lilly has exclusive development, manufacturing and
distribution rights of products in the rest of the world. Lilly will study
JS016 both as a monotherapy as well as in combination with other
antibody treatments including LY-CoV555, its another potential
COVID-19 antibody therapy candidate.
Lilly’s shares have risen 13.6% this year so far against a decrease
of 1.3% for the industry.
Last week, Lilly announced initiation of a phase I study on LY-CoV555,
its lead antibody therapy candidate in collaboration with private biotech,
AbCellera. Lilly signed the deal with AbCellera in March to create
antibody therapies to treat and prevent COVID-19.
More at: finance.yahoo.com
o~~~ O |
